MAP2K7 and neoplasm: Notably, a combination with Gαq inhibitor YM‐254890 and MEK inhibitor showed synergistic growth inhibition and tumor shrinkage.[30] Inspired by this, we combined our Gq inhibitor GQ127 with MEK inhibitor selumetinib, and demonstrated that the combination effectively improves therapeutic efficacy in UM, providing a promising and effective treatment approach in combination regimens.